Floatz Rating
C39/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02659241CT.gov Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peritoneal Carcinomatosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adavosertib (this asset) | M.D. Anderson Cancer Center | Early P1 | C · 39 |
| Fluorouracilum | Ciusss de L'Est de l'Île de Montréal | P3 | BB |
| Muamycin | H. Lee Moffitt Cancer Center and Research Institute | P4 | BB |
| Oxaliplatin | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | P3 | BB |
| Irinotecan | Catharina Ziekenhuis Eindhoven | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P3 | BB |
| Capecitabine | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | P2/3 | BB |
| Indocyanine Green | Jules Bordet Institute | P2 | B |
| Sodium Thiosulfate | National Cancer Institute (NCI) | P2 | B |
+33 more in the Peritoneal Carcinomatosis cohort
Other indications for Adavosertib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Refractory Malignant Neoplasm | — | P2 | B · 62 |
| Female Reproductive Organ Cancer | — | P2 | B · 59 |
| Exocrine Pancreatic Carcinoma | — | P2 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- FluorouracilumCiusss de L'Est de l'Île de MontréalBB
- MuamycinH. Lee Moffitt Cancer Center and Research InstituteBB
- OxaliplatinDaping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityBB
- IrinotecanCatharina Ziekenhuis EindhovenBB
- Cis-Diamminedichloroplatinum IiNational Cancer Institute (NCI)BB
Citation
Floatz Terminal. Adavosertib in Peritoneal Carcinomatosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adavosertib-peritoneal-carcinomatosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →